Clinical Trial Update: Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a peptide-based immunotherapy for head and neck squamous cell carcinoma was terminated; the update reports on trial activity…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Peptide-based immunotherapy

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED